A study performed at the University of São Paulo’s Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungunya virus and yellow fever virus.
“Human cells infected by chikungunya virus were treated with sofosbuvir, and the drug eliminated the virus without damaging any cells. The drug proved to be 11 times more effective against the virus than against cells,” said Rafaela Milan Bonotto, a coauthor of the study.
An article on the study, signed by Bonotto, Freitas-Junior and collaborators, can be found on the open platform F1000Research. An article on the group’s research relating to yellow fever will be published shortly.
The discovery is highly significant for public health, as a chikungunya epidemic has been forecast for the coming two years in Brazil.
“Drug development is extremely costly and time-consuming. The process takes 12 years on average between the start of research and bringing the drug to market. The cost is on the order of US$1.5 billion or more,” Freitas-Junior said. “Sofosbuvir has been fully approved for human use. This means it can be readied for use against chikungunya in one to three years, for a much lower cost, estimated at approximately US$500,000.”
He noted that chikungunya is a severe disease not only owing to the acute episode itself – causing symptoms similar to those of dengue – but because it can cause complications that include highly debilitating joint pain lasting months or years. The patient may become incapacitated, unable to work and even bedridden.
“So far we have no vaccine, and our diagnostic tools need to be optimized,” he continued. “Sofosbuvir is something concrete that could become a powerful weapon against this virus. The results of our research could enable any interested institutions to begin clinical trials.”
Bonotto said, “We don’t yet know exactly how the drug works in molecular terms. What we discovered was the macroscopic result: elimination of the virus and preservation of cells. The drug has proven effective in treating hepatitis C because it inhibits the protein that synthesizes the viral genome. The same may happen in the case of chikungunya, but the action mechanism must be elucidated.”
The Latest on: Sofosbuvir
via Google News
The Latest on: Sofosbuvir
- Taiwan National Health Insurance Adminstration of the Ministry of Health and Welfare Approves Epclusa(R) (sofosbuvir/velpatasvir) for Reimbursementon May 29, 2019 at 11:22 pm
TAIPEI, Taiwan, May 30, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced that Epclusa (sofosbuvir 400mg/velpatasvir 100mg), a once daily pan-genotypic, pan-fibrotic and interferon-free HCV ...
- Sofosbuvir (CAS 1190307-88-0) Market With Thriving CAGR in Forecast Period 2019 to 2026on May 16, 2019 at 11:56 pm
May 17, 2019 (Wired Hearld via COMTEX) -- The new research from Global QYResearch on Global Sofosbuvir (CAS 1190307-88-0) Market Report for 2019 intends to offer target audience with the fresh outlook ...
- A Chinese twist in the tale involving Hepatitis C drug Sofosbuviron February 7, 2019 at 2:03 am
Hepatitis C drug Sofosbuvir has weathered many a storm and in different countries. But a recent development in China involving the drug’s patent has caught the attention of health advocacy ...
- Sofosbuvir rids organism of chikungunya and yellow fever viruseson December 19, 2018 at 4:53 am
A study performed at the University of São Paulo's Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating ...
- Hepatitis Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Have Not Been Treatedon December 6, 2018 at 10:29 am
People living with hepatitis C, access to medicines activists, and the medical community around the world "mark" the fifth birthday of the first all-oral, one dose per day cure sofosbuvir (Sovaldi®), ...
- Sofosbuvir - Indications, Dosage, Side Effects and Precautionson October 31, 2018 at 4:34 am
Latest prescription information about Sofosbuvir. Learn how to pronounce the drug's name, its indications, dosage, how to take, when to take, when not to take, side effects, special precautions, its ...
- Follow-Up Analysis Supporting Cambrex Short Thesison October 16, 2018 at 8:58 am
Contribution margin of sofosbuvir API to Cambrex was likely higher than initially thought, implying the downside on Cambrex share price is more severe than previously presented. Additional data ...
- All Signs Pointing To Trouble At Cambrex - What Happened In Korea Is A Precursoron October 1, 2018 at 2:00 am
ST Pharm, the other major supplier of sofosbuvir API to Gilead foreshadows what will likely happen to CBM. Pricing will be the second leg down with plenty of FDA / EMA approved or ready suppliers ...
via Bing News